IMSA101

IMSA101 is a small molecule analogue of cyclic GMP-AMP (cGAMP) that acts as an agonist of the stimulator of interferon genes protein (STING; also known as TMEM173). By directly activating STING with high potency, IMSA101 induces a robust innate immune response characterized by the secretion of pro-inflammatory cytokines such as IL-18. This immunoactivation leads to enhanced anti-tumor activity and improved efficacy when combined with chimeric antigen receptor T cell (CAR-T) therapy in preclinical models. IMSA101 is being developed primarily for the treatment of advanced or metastatic solid tumors—including non-small cell lung cancer, renal cell carcinoma, gastroesophageal junction carcinomas, hormone receptor negative breast cancer, uveal myeloma, head and neck cancer, hepatoma—as well as hematologic malignancies and refractory cancers. The drug is administered intratumorally and demonstrates improved stability in human serum compared to cGAMP[1][2][5][7].